276 related articles for article (PubMed ID: 36831629)
1. Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target.
Liu G; Zhu M; Zhang M; Pan F
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831629
[TBL] [Abstract][Full Text] [Related]
2. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
3. ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.
Mancarella C; Casanova-Salas I; Calatrava A; Ventura S; Garofalo C; Rubio-Briones J; Magistroni V; Manara MC; López-Guerrero JA; Scotlandi K
Oncotarget; 2015 Jun; 6(18):16611-22. PubMed ID: 25906745
[TBL] [Abstract][Full Text] [Related]
4. Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway.
Pandini G; Genua M; Frasca F; Vigneri R; Belfiore A
Ann N Y Acad Sci; 2009 Feb; 1155():263-7. PubMed ID: 19250214
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
6. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
Fahrenholtz CD; Greene AM; Beltran PJ; Burnstein KL
Oncotarget; 2014 Oct; 5(19):9007-21. PubMed ID: 25344862
[TBL] [Abstract][Full Text] [Related]
7. Crk II silencing down-regulates IGF-IR and inhibits migration and invasion of prostate cancer cells.
Dhupkar P; Zhao H; Mujoo K; An Z; Zhang N
Biochem Biophys Rep; 2016 Dec; 8():382-388. PubMed ID: 28955980
[TBL] [Abstract][Full Text] [Related]
8. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
Fahrenholtz CD; Beltran PJ; Burnstein KL
Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
[TBL] [Abstract][Full Text] [Related]
9. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.
Turney BW; Turner GD; Brewster SF; Macaulay VM
BJU Int; 2011 May; 107(9):1488-99. PubMed ID: 20840329
[TBL] [Abstract][Full Text] [Related]
10. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions.
Tufail M; Wu C
Ther Deliv; 2022 Mar; 13(3):167-186. PubMed ID: 35029130
[TBL] [Abstract][Full Text] [Related]
11. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression.
Sroka IC; McDaniel K; Nagle RB; Bowden GT
Prostate; 2008 Apr; 68(5):463-76. PubMed ID: 18196535
[TBL] [Abstract][Full Text] [Related]
12. 15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells.
Kelavkar UP; Cohen C
Neoplasia; 2004; 6(1):41-52. PubMed ID: 15068670
[TBL] [Abstract][Full Text] [Related]
13. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P
Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314
[TBL] [Abstract][Full Text] [Related]
15. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.
Ryan CJ; Zavodovskaya M; Youngren JF; Campbell M; Diamond M; Jones J; Shiry L; Allan G; Maddux BA; Goldfine ID
Prostate; 2008 Aug; 68(11):1232-40. PubMed ID: 18491370
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
Rieder S; Michalski CW; Friess H; Kleeff J
Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
[TBL] [Abstract][Full Text] [Related]
18. Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.
Chen LH; Fang J; Sun Z; Li H; Wu Y; Demark-Wahnefried W; Lin X
J Nutr; 2009 Apr; 139(4):653-9. PubMed ID: 19211828
[TBL] [Abstract][Full Text] [Related]
19. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
[No Abstract] [Full Text] [Related]
20. Targeting IGF-1 signaling pathways in gynecologic malignancies.
Bruchim I; Werner H
Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
